期刊文献+

HIV-1拉米夫定(3TC)耐药毒株的体外诱导培育和鉴定 被引量:1

Cultivation and identification of 3TC-resistant HIV-1 strain
原文传递
导出
摘要 目的通过体外传代培养,将我国HIV1药物敏感毒株诱导为拉米夫定耐药毒株。方法在MT4细胞中国HIV1B′亚型CNHN24毒株培养系统中加入0.008μmolL拉米夫定,逐渐增加药物浓度进行传代和培养,每隔3~5代测定半数抑制浓度(IC50),并用RTPCR法扩增pol区基因,进行基因型耐药性分析。将表型和基因型耐药结果与敏感株进行比较。结果培养6代后,IC50由野生毒株的0.018μmolL逐渐提高到0.15μmolL;第7代时,IC50突然增加到大于2048μmolL;pol区的184位氨基酸由甲硫氨酸(M)突变为异亮氨酸(I)。去除药物继续培养5代,IC50仍维持>2048μmolL,pol区184位氨基酸仍为异亮氨酸,没有发生回复突变。结论在国内首次用中国HIV1毒株诱导培育出可能稳定传代的3TC耐药株,可用于HIV1耐药性的研究和HIV1药物的药效学评价。该耐药株已申请国家专利。 Objective To gain stable 3TC-resistant HIV-1 strain originated from Chinese HIV-1 B' strain. Methods HIV-1 B' strain isolated from Henan province, China was cultured and passaged with the medium containing double increased 3TC. by 3-5 generations of passage, the 50% inhibitory concentrations of cultures (IC50) were tested. The partial HIV-1 pol gene were amplified and sequenced, the sequence were interpreted with genotypic drug resistance result by the tool from Stanford. Results After 6 generation of passage, the IC50 to 3TC had increased 8.3-fold from 0.008μmol/L to 0.15μmol/L. In the 7^th generation, the IC50 dramatically increased to more than 110 000-fold(2048 μmol/L), genotypic analysis showed that a significant mutation had happened in the position of 184(Met→Ile) of pol gene, the genotype and phenotype of 3TC resistance remained stable after the 5^th generation of cultivation in the absence of drug. Conclsion A rather stable 3TC-resistant variant was established from HIV-CNHN24. This strain can be used for the assessment of the new drug effect and the research of HIV-1 drug resistance.
出处 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2006年第3期220-223,共4页 Chinese Journal of Microbiology and Immunology
基金 卫生部艾滋病防治研究项目攻关课题资助项目(WA200302)
关键词 体外诱导 HIV-1 CNI-IN2A-毒株 拉米夫定 耐药株 Propagation in vitro HIV-1 CNHN24 strains 3TC Drug-resistant variant
  • 相关文献

参考文献6

  • 1Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine(AZT) isolated during prolonged therapy. Science, 1989,243 : 1731-1734.
  • 2Hertogs K, Van Houtte M, Larder B, et al. Testing for HIV-1 drug resistance: new developments and clinical implications. Recent Res Dev Antimicrob Agents Chemother, 1999, 3: 83-104.
  • 3Larder BA, Chesebro BC, Richman DD. Susceptibilities of Zidovudine-susceptible and resistance human immunodeficiency virus isolates to antiviral agents determined by using a quantitive plaque reduction assay. Antimicrob Agent Chemother, 1990, 34: 436-441.
  • 4Kavlick MF, Shirasaka,T, Kojima E, et al. Genotypic and phenotypic characterization of HIV-1 isolated from patient receiving (-)-2', 3'-dideoxy-3'-thiacytidine. Antiviral Res, 1995, 28(2): 133-146.
  • 5Gao Q, Gu ZX, Parniak MA, et al.In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'deoxythymidine and 2', 3'-dideoxyinosine. J Virol, 1992, 66: 12-19.
  • 6Japour AJ, Mayers DL, Johnson VA, et al. A standardized peripheral blood mononuclear cell culture assay for the determination of drug susceptibilities of clinical human immunodeficiency virus-I ( HIV-1 ) isolates.Antimicrob Agents Chemother, 1993, 37: 1095-1101.

同被引文献2

  • 1Li M,Salazar-Gonzalez JF,Derdeyn CA,et al.Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.J Virol,2006,80:11776-11790.
  • 2Platt E J,Wehrly K,Kuhmann SE,et al.Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.J Virol,1998,72:2855-2864.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部